TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19576114

Group type: EXPERIMENTAL
Intervention: Standard dosage targeting goal (SDTG) group - atorvastatin 10 mg/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intensive dosage targeting goal (IDTG) group - atorvastatin 20-80 mg/d
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard dosage non-targeting goal (SDNTG) group - atorvastatin 10 mg/d without targeting goal
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All dosages of atorvastatin (10 mg, 20 mg, 40 mg, 80 mg)
Number of subjects: 102
Study: 17767636

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine (PK) - 1 mg x kg(‐1) ketamine + 1.2 mg x kg(‐1) propofol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol-fentanyl (PF) - 1 microg x kg(‐1) fentanyl + 1.2 mg x kg(‐1) propofol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol-fentanyl (PF)
Number of subjects: 90
Study: 14687871

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-25 mg/day)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Clozapine (100-500 mg/day)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 147
Study: 12405466

Group type: EXPERIMENTAL
Intervention: Pilocarpine dissolved in artificial saliva administered in a mouth spray
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control medicaments
Number of subjects: 23
Study: 9889451

Group type: EXPERIMENTAL
Intervention: Personal letter written in Vietnamese promoting cervical screening
Number of subjects: 689

Group type: COMPARATOR
Intervention: No personal letter (control group)
Number of subjects: 689
Study: 7821274

Group type: EXPERIMENTAL
Intervention: 1 g VGB
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 3 g VGB
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 6 g VGB
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 2399925

Group type: EXPERIMENTAL
Intervention: Imagery condition
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 27
Study: 96473

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg i.v. pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline pretreatment (control)
Number of subjects: 10
Study: 30765242

Group type: EXPERIMENTAL
Intervention: MMRV (two doses of combined measles-mumps-rubella-varicella vaccine)
Number of subjects: 5803

Group type: EXPERIMENTAL
Intervention: MMR + V (one dose of live attenuated varicella vaccine after one dose of measles-mumps-rubella vaccine)
Number of subjects: 5803

Group type: COMPARATOR
Intervention: MMR (two doses of measles-mumps-rubella vaccine)
Number of subjects: 5803
Study: 28676211

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to pemetrexed/cisplatin (PC) chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pemetrexed/cisplatin (PC) chemotherapy alone
Number of subjects: 0
Study: 26070073

Group type: EXPERIMENTAL
Intervention: Compressive forces of 0, 1, 2 and 3 kg/cm2 for 30 seconds
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Infrared thermography performed 15 minutes after contact with the skin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Infrared thermography performed within 60 minutes after contact with the skin
Number of subjects: 15
Study: 24200199

Group type: EXPERIMENTAL
Intervention: Standard dose of Bifilact(®) probiotics (1.3 billion CFU, twice a day)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Standard dose of Bifilact(®) probiotics (1.3 billion CFU, twice a day) in patients who had surgery
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo in patients who had surgery
Number of subjects: 246
Study: 22596211

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg + Methotrexate (MTX)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + Methotrexate (MTX)
Number of subjects: 216
Study: 19058924

Group type: COMPARATOR
Intervention: Non-active control condition (e.g., placebo or attention-only control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validated treatment via a different modality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tests of the new treatment as an add-on to standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of dose-response design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of unequal randomization designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of stopping rules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provision of optimal therapy to those who fail during the study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of the experimental treatment vs. standard treatment
Number of subjects: 0
Study: 17160407

Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg twice daily for 4 weeks, then 10 microg thereafter)
Number of subjects: 501
Study: 15300911

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) with 5 min of ischemia and 5 min of reperfusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no IPC)
Number of subjects: 29
Study: 12078888

Group type: EXPERIMENTAL
Intervention: MEC
Number of subjects: 355

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Stanford V
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 355
Study: 10420106

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% + Timolol 0.5%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Timolol 0.5% + Placebo
Number of subjects: 15
Study: 7497145

Group type: EXPERIMENTAL
Intervention: Retesting with dietary restrictions after an initial positive Haemoccult screening test
Number of subjects: 35260

Group type: COMPARATOR
Intervention: Immediate colonoscopy after a positive Haemoccult screening test
Number of subjects: 35260
Study: 2301216

Group type: EXPERIMENTAL
Intervention: 65% maximal heart rate
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 75% maximal heart rate
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 85% maximal heart rate
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (non-exercise)
Number of subjects: 49
Study: 456272

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.25 mg g-strophanthin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sublingual administration of 6.0 mg g-strophanthin
Number of subjects: 6
Study: 30674348

Group type: EXPERIMENTAL
Intervention: Online self-help program ('Restart') based on cognitive behavioral therapy (CBT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 136
Study: 28497942

Group type: EXPERIMENTAL
Intervention: UpBdResist (upper body resistance exercises followed by 30‐minute cycling at 50%VO2max)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LwBdResist (lower body resistance exercises followed by 30 minutes on an arm‐ergometer)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LwBdResist
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UpBdResist
Number of subjects: 16
Study: 25687364

Group type: EXPERIMENTAL
Intervention: PCL-FM/MTA direct pulp capping
Number of subjects: 60

Group type: COMPARATOR
Intervention: MTA direct pulp capping
Number of subjects: 60
Study: 23392147

Group type: EXPERIMENTAL
Intervention: Sugared chewing gum (Gum) - instructed to chew 3 times daily for 45 minutes each time for 7 days postoperatively
Number of subjects: 114

Group type: COMPARATOR
Intervention: No Gum
Number of subjects: 114
Study: 21248332

Group type: EXPERIMENTAL
Intervention: TS-11-MG vaccine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bacterin + TS-11-MG combined
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bacterin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control M. gallisepticum
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 160
Study: 19283449

Group type: EXPERIMENTAL
Intervention: Adjusted body weight (ABW) dosing of enoxaparin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard dosing of enoxaparin
Number of subjects: 61
Study: 16715020

Group type: EXPERIMENTAL
Intervention: Backpack with abdominal support
Number of subjects: 20

Group type: COMPARATOR
Intervention: No abdominal support
Number of subjects: 20
Study: 16211988

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg orally 3 hours before and 3 hours after the procedure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 61
Study: 12439778

Group type: COMPARATOR
Intervention: 80 Hz electrical stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 Hz electrical stimulation
Number of subjects: 10
Study: 9856543

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (10 mg x kg(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Noncaffeine ingestion (control)
Number of subjects: 11
Study: 8929239

Group type: EXPERIMENTAL
Intervention: GE uncrushed (120 mg myrtol standardized)
Number of subjects: 20

Group type: COMPARATOR
Intervention: GE crushed (120 mg myrtol standardized)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GF uncrushed (300 mg myrtol standardized)
Number of subjects: 20

Group type: COMPARATOR
Intervention: GF crushed (300 mg myrtol standardized)
Number of subjects: 20
Study: 2191783

Group type: EXPERIMENTAL
Intervention: Warfarin administered simultaneously with heparin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin without warfarin therapy
Number of subjects: 0
Study: 419977

Group type: EXPERIMENTAL
Intervention: Pilocarpine eyedrops (2% solution four times daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ocusert P-40 (constant and continuous supply of pilocarpine)
Number of subjects: 16
Study: 31878824

Group type: EXPERIMENTAL
Intervention: Music-contingent gait training for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control music group received 6 weeks of noncontingent music walking followed by 6 weeks of music-contingent training
Number of subjects: 30
Study: 29153992

Group type: EXPERIMENTAL
Intervention: Active implementation intentions (n=18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition (n=17)
Number of subjects: 35
Study: 27507403

Group type: EXPERIMENTAL
Intervention: Polypropylene-based composite mesh
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard polypropylene mesh
Number of subjects: 60
Study: 25389283

Group type: EXPERIMENTAL
Intervention: ZRS >3
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: log NT-proBNP
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: ZRS
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Combined ZRS/NT-proBNP
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: ZRS ≥2 and NT-proBNP ≥200 pg/mL
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Follow-up between 48 hours and 10 days
Number of subjects: 845
Study: 22996693

Group type: EXPERIMENTAL
Intervention: CXCR1/2 allosteric inhibitor reparixin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic and pharmacological blockade of the CXCL1-CXCR1/2 axis
Number of subjects: 0
Study: 20462143

Group type: EXPERIMENTAL
Intervention: SRP + HBO2
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 20
Study: 18662188

Group type: EXPERIMENTAL
Intervention: Intracardiac echo-guided double transseptal access
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pulmonary vein antral isolation (PVAI)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Short-term recurrence of atrial fibrillation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Long-term recurrence of atrial fibrillation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Perioperative complications
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Interatrial communication at 3 months
Number of subjects: 45
Study: 15716162

Group type: EXPERIMENTAL
Intervention: Motor imagery in ideomotor apraxia patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lesions in the intraparietal sulcus
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-apraxic stroke patients
Number of subjects: 19
Study: 12017346

Group type: EXPERIMENTAL
Intervention: Eletriptan (10 to 120 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eletriptan (30 to 90 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10568079

Group type: EXPERIMENTAL
Intervention: Nursing Assistant Communication Skills Program (NACSP)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Wait-list control condition (UC)
Number of subjects: 2
Study: 8602179

Group type: EXPERIMENTAL
Intervention: Beta carotene (50 mg on alternate days)
Number of subjects: 22071
Study: 1751651

Group type: EXPERIMENTAL
Intervention: Chlorazepam as oral premedication (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No premedication (n = 25)
Number of subjects: 50
Study: 7040131

Group type: EXPERIMENTAL
Intervention: Tigason
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30388595

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus Plantarum 299v (LP299v) with SSRI, n=40
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo with SSRI, n=39
Number of subjects: 79
Study: 30195882

Group type: EXPERIMENTAL
Intervention: Garlic supplement (1000 mg, twice daily for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27186859

Group type: EXPERIMENTAL
Intervention: Serum 25OHD levels measured
Number of subjects: 540
Study: 24930178

Group type: EXPERIMENTAL
Intervention: Visual-manual distraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-audio distraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous distraction condition
Number of subjects: 0
Study: 22169398

Group type: EXPERIMENTAL
Intervention: Recommended fluid intake (mean amount 2427 ml)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Low fluid intake (mean amount 1625 ml)
Number of subjects: 465
Study: 19765674

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day for 4 weeks, then 40 mg/day for 4 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: Citalopram vs Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 54
Study: 16959466

Group type: EXPERIMENTAL
Intervention: Video information combined with individualized information sessions
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standardized information without video
Number of subjects: 109
Study: 15793869

Group type: EXPERIMENTAL
Intervention: Autologous HBsAg-loaded dendritic cells (DCs)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: DCs and lamivudine
Number of subjects: 19
Study: 12060531

Group type: EXPERIMENTAL
Intervention: Single oral administration of leflunomide (20 mg, 40 mg, 60 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Repeated oral administration of leflunomide (20 mg/d for 30 days)
Number of subjects: 24
Study: 10199110

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 15 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 8578014

Group type: EXPERIMENTAL
Intervention: Aerosol inhalation of fenoterol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous route of fenoterol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nasal instillation of fenoterol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metered dose inhalers (MDI) inhalation of fenoterol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aerosol inhalation of 200 micrograms of fenoterol
Number of subjects: 27
Study: 1415101

Group type: EXPERIMENTAL
Intervention: Wilson Cook disposable cytology brush
Number of subjects: 78

Group type: COMPARATOR
Intervention: Other disposable cytology brushes (Microvasive, Mill-Rose, Hobbs)
Number of subjects: 78
Study: 4054195

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg once-daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: pindolol 20 mg slow release (SR) once-daily
Number of subjects: 107
Study: 31790481

Group type: COMPARATOR
Intervention: HIV- group (n=162)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Higher PASE
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Greater enjoyment of PA
Number of subjects: 250

Group type: COMPARATOR
Intervention: HIV- participants
Number of subjects: 250
Study: 29710322

Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Milk chocolate
Number of subjects: 30
Study: 27117853

Group type: EXPERIMENTAL
Intervention: Resistant Glucan Mixture (RGM) 13.2 g/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resistant Glucan Mixture (RGM) 6.6 g/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resistant Glucan Mixture (RGM) 3.3 g/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (digestible maltodextrin)
Number of subjects: 60
Study: 26307122

Group type: EXPERIMENTAL
Intervention: Supportive therapy for proximal plantar fasciitis (type of foot support not specified)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Biconvexity of the plantar fascia on sonography at presentation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Changes in self-reported pain over the 3-month study period
Number of subjects: 70
Study: 23279560

Group type: EXPERIMENTAL
Intervention: Modest compensation for submitting dated time-stamped BrAC videos
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with escalating vouchers for on-time alcohol-negative tests (n-BrAC; <0.02 g/dl)
Number of subjects: 30
Study: 21700935

Group type: EXPERIMENTAL
Intervention: Group 3b (eGFR 30.0 to 44.9 mL/min/1.73 m²)
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Group 3a (eGFR 45.0 to 59.9 mL/min/1.73 m²)
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Group 2 (eGFR 60.0 to 89.9 mL/min/1.73 m²)
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Group 1 (eGFR ≥ 90.0 mL/min/1.73 m²)
Number of subjects: 1312
Study: 19086960

Group type: EXPERIMENTAL
Intervention: mesalamine foam 1 g/80 mL/day
Number of subjects: 375

Group type: COMPARATOR
Intervention: mesalamine liquid enema 1 g/100 mL/day
Number of subjects: 375
Study: 17238390

Group type: EXPERIMENTAL
Intervention: ATHENA advisories
Number of subjects: 46

Group type: COMPARATOR
Intervention: Quality-assurance algorithms
Number of subjects: 46
Study: 14996064

Group type: EXPERIMENTAL
Intervention: Chloroatranol 5 p.p.m. solution applied for 14 days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chloroatranol 25 p.p.m. solution applied for additional 14 days if no reaction to 5 p.p.m.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patch testing with chloroatranol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no chloroatranol exposure)
Number of subjects: 23
Study: 10723239

Group type: EXPERIMENTAL
Intervention: Reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 29
Study: 9003815

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hematologic management for hemorrhagic cerebrovascular accident
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evacuation of the hematoma
Number of subjects: 0
Study: 8195911

Group type: EXPERIMENTAL
Intervention: Computer-generated recommendations for scheduling the next visit
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group (no computer-generated recommendations)
Number of subjects: 620
Study: 3068400

Group type: EXPERIMENTAL
Intervention: Streptokinase treatment (1,000,000 units over 60 min)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase administration (120,000‐180,000 units over 60‐90 min)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Patients with regained coronary flow
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Patients with persisting coronary occlusion
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intravenous and intracoronary routes of administration
Number of subjects: 87
Study: 30451184

Group type: EXPERIMENTAL
Intervention: Circumferential incisions
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Radial incisions
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Superonasal quadrant sclerotomies
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inferotemporal quadrant sclerotomies
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Superotemporal quadrant sclerotomies
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sclerotomies to the left of the surgeon
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sclerotomies to the right of the surgeon
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Gas tamponade
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Oil tamponade
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: No tamponade
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Radial sclerotomies without tamponade
Number of subjects: 46
Study: 27455835

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25420736

Group type: EXPERIMENTAL
Intervention: 4 L PEG + bisacodyl 10 mg
Number of subjects: 196

Group type: COMPARATOR
Intervention: PEG only group (4 L PEG)
Number of subjects: 196
Study: 23011562

Group type: EXPERIMENTAL
Intervention: Phenylephrine bolus (120 μg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phenylephrine infusion (120 μg/min)
Number of subjects: 60